Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
U.S. health reviewers are concerned that clinicians may not be able to properly interpret brain scans using Eli Lilly & Co.’s imaging agent for Alzheimer’s and that the tests may be of limited use in assessing the degenerative disease.
The radioactive dye is intended for use with positron emission tomography, or PET, scans that help detect the presence of beta-amyloid plaques linked to Alzheimer’s disease. Get the full story »
The chief of drugmaker Eli Lilly & Co. said Wednesday that he expects the bulk of this year’s U.S. health care overhaul to remain intact despite Tuesday’s election victories by anti-overhaul Republicans.
But with Republicans taking control of the House of Representatives from the Democrats, Chief Executive John Lechleiter said he will lobby to overturn at least one provision of the overhaul: the creation of an independent payment advisory board tasked with controlling growth in spending by Medicare. Get the full story »
A majority of federal health advisers say a best-selling antidepressant from Eli Lilly & Co. appears effective in treating back pain, but not arthritis.
The Food and Drug Administration is considering whether to broaden approval of Cymbalta to treat chronic pain, which would expand sales of a drug already used by 15 million U.S. patients. Get the full story »
Eli Lilly and Co. halted development of an Alzheimer’s drug after it worsened patients’ symptoms in late-stage studies, dealing a fresh blow to the U.S. drugmaker and to research to fight the disease.
The Alzheimer’s setback comes as U.S. regulators raised concerns about using Lilly’s antidepressant Cymbalta to treat chronic pain and follows patent case losses on two other key products in the last month. Get the full story »
